Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–65 of 65 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pain Crisis Clear all

Conditions: Sickle Cell Disease
Interventions: Hydromorphone (Standardized, weight-based dosing), Morphine Sulfate (Standardized, weight-based dosing), Hydromorphone (Patient Specific dosing), Morphine Sulfate (Patient Specific dosing); Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Sickle Cell, Sickle Cell Disease, Sickle Cell Disease Without Crisis, Mediterranean Diet
Interventions: Mediterranean Diet, Usual Diet; Other
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sickle Cell Disease
Interventions: SelG1, Placebo; Drug
Lead sponsor: Reprixys Pharmaceutical Corporation; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 49
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: HEMOGLOBIN SC DISEASE
Interventions: Mg Pidolate, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
Interventions: telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment; Behavioral · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 35 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions: music therapy; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Suvankar Majumdar; Other
Eligibility: 4 Years to 21 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Placebo, Dalteparin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: methadone hydrochloride, morphine sulfate, oxycodone hydrochloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Spartanburg, South Carolina • Houston, Texas

Conditions: Hemoglobin SC Disease
Interventions: Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid; Drug · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more

Conditions: Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss, Hbsc, Sickle Beta Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Syndrome Variant
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 16 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Ketamine; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 7 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sickle Cell Anemia
Interventions: L-NMMA, Sodium Nitrite; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions: Inclacumab, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 17
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more

Conditions: Sickle Cell Disease, Sickle Cell Crisis, Pain, Acute
Interventions: Lidocaine Iv, Placebo; Drug
Lead sponsor: Community Medical Center, Toms River, NJ; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Long Branch, New Jersey • New Brunswick, New Jersey • Newark, New Jersey

Conditions: Sickle Cell Disease
Interventions: Crovalimab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Detroit, Michigan • Madison, Mississippi • New York, New York + 1 more

Search by objective public record fields.

Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease

Sickle Cell, Pain and Mediterranean Diet

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate

Quality of Life in Younger Leukemia and Lymphoma Survivors

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease

Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis

A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)